Addex Therapeutics Ltd (ADXN) Bundle
An Overview of Addex Therapeutics Ltd (ADXN)
General Summary of Addex Therapeutics Ltd (ADXN)
Addex Therapeutics Ltd is a biopharmaceutical company headquartered in Geneva, Switzerland, focusing on developing novel small molecule allosteric modulators for neurological and psychiatric disorders.
Company Products and Services
- ADX71441 - Glutamate receptor modulator
- ADX71149 - Parkinson's disease treatment candidate
- Dipraglurant - Potential treatment for dystonia and Parkinson's disease
Financial Performance (2024)
| Financial Metric | Amount (USD) |
|---|---|
| Total Revenue | $3.2 million |
| Research & Development Expenses | $12.5 million |
| Net Loss | $9.7 million |
| Cash and Cash Equivalents | $15.6 million |
Industry Leadership
Addex Therapeutics specializes in developing innovative allosteric modulation therapeutics, with a focus on neurological disorder treatments.
- Nasdaq listed company (ADXN)
- Pioneering glutamate receptor modulation technology
- Ongoing clinical trials in multiple neurological indications
Mission Statement of Addex Therapeutics Ltd (ADXN)
Mission Statement of Addex Therapeutics Ltd (ADXN)
Addex Therapeutics Ltd (ADXN) mission statement focuses on innovative pharmaceutical development targeting neurological and rare disorders.
Core Mission Components
| Component | Specific Focus | Key Metrics |
|---|---|---|
| Innovative Drug Discovery | Allosteric modulator technologies | 4 active drug development programs |
| Neurological Disorder Treatment | Parkinson's, Fragile X syndrome | 2 clinical-stage therapeutic candidates |
| Research Investment | Advanced pharmaceutical platforms | $14.2 million R&D expenditure (2023) |
Strategic Research Priorities
- Develop precision medicine approaches
- Target neurological rare diseases
- Utilize proprietary ADX platform technologies
Research Portfolio Highlights
Current research pipeline includes:
- ADX71441 - Parkinson's disease treatment
- ADX78267 - Fragile X syndrome therapeutic
Financial Research Investment
| Year | R&D Expenditure | Percentage of Budget |
|---|---|---|
| 2022 | $12.8 million | 68% |
| 2023 | $14.2 million | 72% |
Clinical Development Metrics
Current Clinical Stage Candidates: 2 therapeutic candidates in clinical development
Target Patient Populations: Neurological rare disease patients
Vision Statement of Addex Therapeutics Ltd (ADXN)
Vision Statement of Addex Therapeutics Ltd (ADXN)
Strategic Vision FrameworkAddex Therapeutics Ltd (ADXN) focuses on developing innovative allosteric modulator therapeutics targeting rare disorders and neurological conditions.
Core Vision Components
Neurological Disease InnovationADXN targets specific neurological disorders with unmet medical needs, concentrating on:
- Parkinson's disease treatment development
- Epilepsy therapeutic interventions
- Movement disorders pharmaceutical solutions
| Research Category | Investment (2024) |
|---|---|
| Total R&D Expenditure | $12.4 million |
| Neurological Disorder Programs | $7.8 million |
| Rare Disease Therapeutic Research | $4.6 million |
ADXN maintains a focused pipeline targeting:
- ADX71149 for Parkinson's disease
- ADX71441 for epilepsy management
- Metabotropic glutamate receptor modulators
| Technology Platform | Capability |
|---|---|
| Allosteric Modulation | Precision targeting of receptor interactions |
| Chemical Libraries | Over 6,000 proprietary compounds |
| Patent Portfolio | 24 active global patents |
Core Values of Addex Therapeutics Ltd (ADXN)
Core Values of Addex Therapeutics Ltd (ADXN)
Innovation and Scientific Excellence
Addex Therapeutics demonstrates commitment to innovation through its allosteric modulator drug discovery platform. As of 2024, the company has:
- 3 active drug discovery programs
- 2 clinical-stage therapeutic candidates
- $12.4 million invested in R&D for 2023
| Research Area | Investment | Program Status |
|---|---|---|
| Neurological Disorders | $5.2 million | Advanced Stage |
| Metabolic Diseases | $4.7 million | Clinical Development |
| Rare Genetic Conditions | $2.5 million | Preclinical Research |
Patient-Centric Approach
Addex Therapeutics prioritizes patient needs through targeted therapeutic development:
- 2 rare disease programs in active development
- Collaboration with 3 patient advocacy groups
- Clinical trial participation across 5 countries
Ethical Research and Transparency
The company maintains rigorous ethical standards in drug development:
| Ethical Metric | Compliance Level |
|---|---|
| Clinical Trial Transparency | 100% registered on ClinicalTrials.gov |
| Regulatory Compliance | FDA and EMA Approved Protocols |
| Data Sharing Commitment | Quarterly Comprehensive Reports |
Collaborative Scientific Ecosystem
Addex Therapeutics engages in strategic partnerships:
- 7 active academic research collaborations
- 4 pharmaceutical industry partnerships
- $3.6 million allocated to collaborative research
Addex Therapeutics Ltd (ADXN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.